Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYNRCS-Allo inj in ALS
NCT03214146Phase 1Unknown
- Sponsor
- Hanyang University
- Start
- Feb 2017
- Primary completion
- Mar 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HYNRCS-Allo in amyotrophic lateral sclerosis (ALS), sponsored by Hanyang University. Primary endpoint: Incidence of any treatment related serious adverse events at 12 months. Status: unknown.
02
Drugs
HYNRCS-Allo
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03214146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03214146.